Preparat: Aldactone®, Spironolacton AL, Spironolactone Accord, Spironolactone Orion, Spironolakton Pfizer, Spironolakton Takeda
ATC kod: C03DA01
Spironolakton används bland annat för behandling av hypertoni och som tilläggsbehandling vid allvarlig hjärtsvikt. Vissa studier av den blodtryckssänkande effekten av spironolakton har visat avsaknad av könsskillnader, medan andra studier har visat större effekt hos framförallt postmenopausala kvinnor.
Spironolakton reducerar risken för sjuklighet och död hos patienter med allvarlig hjärtsvikt. Effekten är likvärdig hos kvinnor och män.
Spironolakton kan blockera androgenreceptorn och därmed ge upphov till hormonella biverkningar hos både kvinnor och män. Män som tar spironolakton har en ökad risk att få gynekomasti vid högre doser och långtidsanvändning. Om så inträffar rekommenderas byte till eplerenon alternativt dossänkning.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics of spironolactone have been found. Effective reduction in blood pressure could be obtained also with lower doses (25-50 mg/day) of spironolactone. A lower dose may reduce the problem with sex steroid-related adverse effects , in particular the dose-dependent side effect gynecomastia in men [2, 3].
Studies analyzing sex differences in blood pressure reduction after spironolactone treatment report contradictory results. The effect of spironolactone on blood pressure was evaluated among hypertensive patients in the ASCOT-BPLA trial (1091 men, 320 women), a large-scale, randomized, controlled study. Overall, similar reductions in blood pressure (BP) were observed in men and women. However, there were modest but significantly greater reduction in diastolic BP among women compared with men. This difference did not differ after adjustment for pre-spironolactone BP levels .In a post-hoc analysis of the APIRANT trial (37 men, 18 women), treatment with 25 mg spironolactone once daily or placebo for 8 weeks in patients with resistant hypertension, resulted in similar reductions in systolic and diastolic BP in men and women .One study on primary-care hypertensive patients (45 men, 45 women) treated with potassium kanrenoate (the active metabolite of spironolactone), reported that the drug was twice as effective in reducing systolic BP in women compared to men after 2 months of treatment. A subgroup analysis of the results showed that the larger effect was obtained in postmenopausal women, suggesting a role of aldosterone in these patients .
The favorable effect of spironolactone on heart failure related mortality appears to be similar for both men and women [7, 8].
Because of its non-selective binding to the mineralocorticoid receptor, spironolactone can antagonize the androgen receptor causing a variety of sexual adverse events in both men and women . Clinical trials have reported gynecomastia as a commonly sex hormone-related adverse event in men [3, 4, 8]. In the RALES study, examining the effect of 25 mg spironolactone on symptomatic heart failure patients (1217 men, 446 women), 10% of men taking spironolactone complained of gynecomastia and/or breast pain, as compared with 1% of men in the placebo group . Also in the ASCOT trial (1091 men, 320 women), analyzing the effect of 25-50 mg spironolactone on blood pressure, gynecomastia or breast discomfort was recorded as an adverse event in 6% of spironolactone treated patients (all men), resulting in discontinuation in 3.7%. However, as the study was not focused on adverse events of spironolactone, the authors suggested gynecomastia could be more common .
The risk of gynecomastia should not be an argument against the use of spironolactone in men with severe heart failure, since spironolactone reduces the risk of both morbidity and death [k1] . If gynecomastia occurs, switching to eplerenone might be an option.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Treatment and 6-month outcome were compared among men and women in a prospective cross-sectional Italian study in heart failure patients (1127 men, 1000 women) admitted to hospital. Women were less frequently treated with spironolactone compared with men in-hospital. At discharge, spironolactone was less frequently prescribed to women. A possible explanation to this might be that spironolactone is not used in patients with preserved left ventricular function, which included many of the women in this study . Spironolactone is more used in women with hypertension but apparently not in heart failure.
Fler kvinnor än män hämtade ut spironolakton (ATC-kod C03DA01) på recept i Sverige år 2018, totalt 52 938 kvinnor och 43 692 män. Det motsvarar 11 respektive 9 patienter per tusen invånare. Andelen som hämtat ut läkemedlet ökade med stigande ålder hos båda könen. I genomsnitt var spironolakton 2,7 gånger vanligare hos kvinnor .
Faktagranskat av: Mia von Euler
Godkänt av: Karin Schenck-Gustafsson